dr. reck on the safety of pembrolizumab in keynote-024 in metastatic nsclc
Published 3 years ago • 301 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
3:04
keynote-024 update: pembrolizumab vs platinum-based chemotherapy in nsclc
-
3:31
the keynote-024 precedent for advanced-nsclc treatment
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
5:53
martin reck:
-
1:02
pembrolizumab monotherapy for nsclc: keynote-024 update
-
1:20
pembro continues to demonstrate os benefit in first-line nsclc: keynote-024 update
-
4:57
keynote-024 shows prolonged nsclc survival benefit with pembrolizumab | julie brahmer
-
1:55
dr. kim on the keynote-189 trial in metastatic nsclc
-
0:30
copy of dr. camidge on the keynote-024 trial in nsclc
-
4:47
benefit of pembrolizumab in nsclc: the keynote trials
-
1:22
updated outcomes of keynote-010 of pembrolizumab for nsclc
-
1:13
a new standard of care for advanced lung cancer: what’s next for pembrolizumab?
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
8:44
upfront immunotherapy for pd-l1 nsclc
-
2:09
dr. reck on the impower150 study
-
1:49
dr. herbst on the impact of frontline immunotherapy in lung cancer
-
3:19
frontline pd-l1 monotherapy: keynote-042 and impower110
-
1:37
keynote-010 shows overall survival benefit of pembrolizumab in nsclc
-
3:47
a keynote on pd-l1 as a predictive biomarker of immunotherapy response: a complex picture